Entrepreneurial investor pitch on a CAR-T switchable technology: The exercise has been done to understand how venture capital works and how to promote a start-up.

1. SWITCH INVESTOR PITCH
SWITCHABLE CAR-T CELL INNOVATION THERAPY
MS Biotech 2018-2019
Soumiya Amellah - Yasmine Benlounes - Diane Bugeaud -
Mohamed Kaabouni - Margot Naëgelé- Alexandre Trichies

2. Our startup is based in the Silicon
Valley, California, USA.
FOUNDED 5 YEARS AGO
We have 6 people in our team with dual
competences both in science and in
business.
OUR TEAM
Switchable CAR-T Cell therapy
End of preclinical studies stage
TECHNOLOGY

3. Our Team
Alexandre Trichies
CEO
You can simply impress
your audience and add
a unique zing.
Name Here
Programmer
You can simply impress
your audience and add
a unique zing.
Name Here
Programmer
You can simply impress
your audience and add
a unique zing.
Soumiya
COO
You can simply impress
your audience and add
a unique zing.
Mohamed
Kaabouni
CEO
Soumiya
Amellah
COO
Yasmine
Benlounes
CTO
Diane
Bugeaud
CSO
Alexandre
Trichies
CFO
Margot
Naëgelé
Business
development

4. Situation : What does the firm do?
Chimeric Antigen Receptor T-cell (CAR-T) therapies
Modern PowerPoint
Presentation
● Harness the
power of a
cancer patient's
own immune
system to attack
and destroy
cancer cells
● "Switchable"
CAR-T cell

5. Situation : What need are we addressing ?
SWITCH is aiming to treat
cancer and, particularly,
hematological or solid tumor
cancers
SWITCH
Limitation of current CAR-T
therapies: serious adverse
events
Why?
Patients with hematological and
solid tumor cancers
Who is the customer? - Cytokine release syndrome
- Neurologic events
- Low white blood cell count
- Low red blood cell count
Adverse events

6. Task : What is your competitive advantage?
Clinical challenges Conventional CAR-T Switchable CAR-T
Safety Low High
Efficacy on solid tumors No Yes
Standardized protocol No Yes
Tunable No Yes
Cost of therapy High
Single vector design expected to
decrease end-cost
- Enhance safety, versatility and efficacy
- Control the activation and antigen specificity of CAR-T cells

7. How big is our Market ?
18.1 million new cases per
year worldwide
In 2018 : 9.6 million
deaths due to cancer worldwide
Cost of cancer : $1.16 trillion
estimated in 2010

8. Exit strategy : Initial Public Offer
Precision Bioscience :
❖ IPO on 03/27/2019
❖ 7,900,000 stocks offered
❖ Share price : 16,00 $
❖ 126,400,000 $
❖ Current share price : 15,00 $
Our IPO :
❖ Exit date : 2024
❖ 5 years of financing
❖ Achieve Phase III
❖ Estimated value : 275 M$

9. Exit strategy : Merger and Acquisition
Private company
Developed Car-T cells therapy
Clinal phase 3
Why M&A might be a good exit strategy ?
Acquisition in 2017 for $11.9 Billion
$180.00 per share
➔ Immediately positions Gilead to be a Global Leader in Oncology and Cell Therapy
"The field of cell therapy has advanced very quickly, to the point where the science and technology
have opened a clear path toward a potential cure for patients.”
JOHN F. MILLIGAN, PHD
GILEAD’S PRESIDENT & CHIEF EXECUTIVE OFFICER

10. Exit strategy : Merger and Acquisition
2020 2021 2022
End of the
Phase 2 b
M&A
An Attractive opportunity
● Patent expiration of Humira in 2018
● Looking for innovation
● Need to follow the trends of the competitors
(Gilead, Novartis…)
● Big Innovation
● High expertise
● Attractive field for companies
Our plan
-M&A in 3 years
-Estimated price : 180 M

11. Investment Needed
● Granted from NIH since the corporation arised
● We are at the end of the Pre-Clinical phase
● Seeking for new investment
Actual position :
$25M in Serie A round
Investment Targeted
● Start Phase 2
● Through Human Clinical
Trial
Clinical Trial process
● Hiring : Head of Clinical, 3
Technicians, Head of IP (patents …)
● CAPEX and OPEX investment
Corporation Growth
Company Serie A
Autolus Therapeutics $30M
MolMed SpA $58M
Crispr Therapeutics $25M
Precision Biosciences $25M
TILT Biotherapeutics $12M

12. What are we offering ?
$25M
⅓ of the company
(Pre-money value of $50M)
Convertible preferred
shares
Two possible exits:
● M&A after 3 years
● IPO after 5 years

13. What are we offering ?
In the case of an Acquisition Three years after entering Switch:
26%
34%
43%
$50M
$60M
$73M
IRR

14. What are we offering ?
In the case of an IPO Five years after entering Switch:
27%
29%
32%
$83M
$92M
$100M
Even with a possible dilution of 20%, the internal
rate of return will stay between: 22,5% and 26,6%
IRR

15. Thank you
Any questions?

16. References
https://news.abbvie.com/news/abbvie-and-calibr-announce-collaboration-for-next-generation-t-cell-therapies.htm
https://www.ncbi.nlm.nih.gov/pubmed/?term=Switch-
Mediated+Activation+of+Retargeting+of+CAR+T+cells+for+B+cell+Malignancies
https://www.ajmc.com/newsroom/abbvie-and-calibr-to-collaborate-on-car-t-cell-development
CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, Control of CAR-T Cell Therapy Using Bio-Orthogonal
Switches Travis S Young Principal Investigator, Calibr.
https://www.who.int/en/news-room/fact-sheets/detail/cancer